In a move to progress treatment efficacy, oncologists widely agree that, in the future, cancer treatments will become ...

UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) ...

Argenx has presented positive phase 2 results for efgartigimod in myositis and Sjogren’s disease at EULAR 2025. The company ...

Tagomics has been awarded £860k in funding from Innovate UK’s Biomedical Catalyst programme to develop a novel diagnostic ...

The PharmaTimes Clinical Researcher of the Year – The Americas 2025 Awards offer an unparalleled opportunity to showcase your ...

Tozaro has announced the appointment of Dr Jason Slingsb y as Chief Executive Officer. Jason will lead the company’s ...

Clinigen has appointed Nihad Hasagic as Senior Vice President for Clinigen Lifecycle Services (SVP CLS). CLS plays a key role in Clinigen’s growing service portfolio, helping to facilitate accelerated ...

Santen has announced that the European Commission has granted market authorisation for Ryjunea, a low-dose atropine eye drop ...

Birmingham spin-out Linear Diagnostics has secured £1m funding to advance a rapid test for sexually transmitted infections ...

Sogroya acts as a replacement for endogenous growth hormone and is administered once a week to support growth in children ...

Flip feasibility: from capacity and capability to human realities True feasibility begins with understanding the patient.

The National Institute for Health and Care Excellence (NICE) has published updated guidance recommending Forxiga ...